213 related articles for article (PubMed ID: 3730331)
1. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
[TBL] [Abstract][Full Text] [Related]
3. Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Gynecol Obstet Invest; 1989; 27(2):102-4. PubMed ID: 2731767
[TBL] [Abstract][Full Text] [Related]
4. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
6. Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.
Menczer J; Modan M; Brenner J; Ben-Baruch G; Brenner H
Gynecol Oncol; 1986 Jun; 24(2):149-54. PubMed ID: 3710262
[TBL] [Abstract][Full Text] [Related]
7. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
9. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
11. Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985.
Watring W; Semrad N; Alaverdian V; Latino F; Pretorius G
Gynecol Oncol; 1989 Feb; 32(2):245-7. PubMed ID: 2910787
[TBL] [Abstract][Full Text] [Related]
12. Second-look laparotomy after chemotherapy in the management of ovarian malignancy.
Smirz LR; Stehman FB; Ulbright TM; Sutton GP; Ehrlich CE
Am J Obstet Gynecol; 1985 Jul; 152(6 Pt 1):661-8. PubMed ID: 4040706
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
[TBL] [Abstract][Full Text] [Related]
14. Second look laparotomy in the management of epithelial cell carcinoma of the ovary.
Mead GM; Williams CJ; MacBeth FR; Boyd IE; Whitehouse JM
Br J Cancer; 1984 Aug; 50(2):185-91. PubMed ID: 6466536
[TBL] [Abstract][Full Text] [Related]
15. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
17. Primary chemotherapy and the role of second-look laparotomy in non-dysgerminomatous germ cell malignancies of the ovary.
Pippitt CH; Cain JM; Hakes TB; Pierce VK; Lewis JL
Gynecol Oncol; 1988 Oct; 31(2):268-75. PubMed ID: 2458993
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
Piver MS; Malfetano J; Baker TR; Lele SB; Marchetti DL
Gynecol Oncol; 1989 Oct; 35(1):69-72. PubMed ID: 2792905
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]